2 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 5 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Ipilimumab Injection: new trials by email Literature Review of Ipilimumab Injection trials Research Report on Ipilimumab Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial Ipilimumab Injection, Sintilimab injection, Lenvatinib - Renal Cell Carcinoma (Kidney Cancer), Immunotherapy | Phase 2 | Not yet recruiting | West China Hospital | 66 | 2026-08-01 | 2026-07-20 |
| XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer XH001, Ipilimumab Injection, Sintilimab injection - Pancreatic Cancer | Not applicable | Recruiting | Wu Wenming | 28 | 2024-03-12 | 2026-02-13 |
| Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy Ipilimumab Injection, Atezolizumab Injection, Bevacizumab - HCC - Hepatocellular Carcinoma, Metastatic Cancer | Phase 2 / Phase 3 | Completed | Federation Francophone de Cancerologie Digestive | 229 | 2023-03-09 | 2026-03-09 |
| Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab - Melanoma, Unresectable Melanoma | Phase 2 | Recruiting | NYU Langone Health | 105 | 2023-02-02 | 2026-01-05 |
| Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Nivolumab Injection, Ipilimumab Injection - Mesothelioma | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 30 | 2019-10-02 | 2026-06-05 |
| Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Cryotherapy, Ipilimumab Injection - Melanoma (Skin) | Phase 1 / Phase 2 | Completed | University Hospital, Strasbourg, France | 19 | 2019-08-16 | 2026-06-05 |
Melanoma (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Kidney Neoplasms (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
Federation Francophone de Cancerologie Digestive (1) · NYU Langone Health (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University Hospital, Strasbourg, France (1) · West China Hospital (1) · Wu Wenming (1)
China (2) · France (2) · United States (2)
Hao Zeng, Doctor (1) · Janice Mehnert, MD (1) · Julie Brahmer, MD (1) · Wenming WU, Prof. (1)
PMID 38570342, PMID 40921804, PMID 42330996
2018 (1)